Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mammalian Deoxyribonucleic Acid (DNA) is the fundamental hereditary material located within the nucleus and mitochondria of cells, carrying the genetic instructions necessary for the development, survival, and reproduction of the organism [NIH, 2023]. It consists of two polynucleotide strands forming a double helix, which serves as the template for both its own replication and the transcription of genetic information into RNA [Wikipedia, 2024]. In clinical medicine, DNA is a critical therapeutic target, particularly for cytotoxic chemotherapy used to treat various cancers [StatPearls, 2023]. Drugs such as alkylating agents and intercalators interact directly with the DNA structure to impede replication and induce apoptosis in malignant cells [PubChem, 2024]. While highly effective at reducing tumor burden, these agents often lack cellular specificity, leading to damage in healthy, rapidly dividing tissues like the bone marrow and gastrointestinal tract [PubMed, 2022]. Consequently, the use of DNA-targeting drugs requires careful monitoring for systemic toxicities and long-term risks such as secondary cancers [NIH, 2023].
Drugs targeting mammalian DNA primarily function by inducing structural damage that inhibits essential cellular processes. This includes the formation of covalent cross-links (alkylating agents), intercalation between base pairs (anthracyclines), and the induction of single- or double-strand breaks through the inhibition of topoisomerase enzymes or direct oxidative damage [StatPearls, 2023; PubChem, 2024]. These modifications disrupt DNA replication and transcription, ultimately activating DNA damage checkpoints and triggering programmed cell death (apoptosis) in rapidly proliferating cells [NIH, 2023].
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mammalian Deoxyribonucleic Acid (DNA) (DNA).